Oireachtas Health Committee seek age restrictions on e-cigarettes and ban on flavourings

Regulations
Jul.19.2022
The committee asked the Minister for Health to look at other countries where ages for vaping and smoking are 21.

A BAN ON flavoured e-cigarettes, e-cigarette ads on social media and bright packaging are just some of the restrictions recommended in a report on pre-legislative scrutiny on a  public health bill published on the weekend.

Oireachtas Health Committee seek age restrictions on e-cigarettes and ban on flavourings

 

The Oireachtas joint committee on health compiled suggestions for the Public Health (Tobacco and Nicotine Inhaling Products) Bill 2019 after meeting with health specialists and representatives of the vaping industry.

 

A key recommendation was that the bill should regulate the flavouring of e-cigarettes and that all flavours except for tobacco, should be strictly prohibited so as not to entice minors.

 

Speaking to the committee, the Irish Heart Foundation called e-cigarette flavours marketing tools “that are almost exclusively directed at young people because if young people are not addicted, there is no business model.”

 

The committee has stated that the Minister for Health should review international studies to consider increasing the age for buying tobacco and nicotine-inhaling products  to 21.

 

Also giving evidence to the committee, the Royal College of Physicians in Ireland (RCPI) stated that teenagers are more likely to use flavoured nicotine products than other age groups.

 

However, the RCPI also told the committee that a recent study examining the effects of a similar ban in Finland did not report a significant change in e-cigarette use post introduction.

 

Many of the proposals made by the committee indicate a desire to treat e-cigarettes more like traditional cigarettes, such as a move to introduce plain packaging rather than what the Irish Cancer Society has called “cartoon-type packaging”.

 

According to a 2019 European School Survey Project on Alcohol and Other Drugs (ESPAD) vaping among young people is now more common than smoking and more young people aged 12-17 years have tried vaping (22%) compared to adults (14%).

 

The survey also found that in 15 and 16 year olds, almost four in 10 students (39%) had tried e-cigarettes and almost one in 5 (18%) were current users.

 

However, the sale of e-cigarettes to under-18s is still not against the law despite the fact that public health officials as well as representatives of the vaping industry have been advocating for it for years.

 

In response to the report’s publication Vape Business Ireland stated that the complexity of the suggestions would only delay the bill and the under-18s ban.

 

It also claimed that the committee referred to “outdated evidence, as well as research which falls short of international standards”.

 

Another measure in the report would ban the sale of e-cigarettes from temporary units such as kiosks, stalls or marquees at festivals and introduce a license for approved sellers.

 

The report also urges that the bill  contain measures to ban all forms of e-cigarette advertising on billboards, online on all social media platforms, and influencer marketing methods.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei Industrial Co., Ltd. disclosed several oral nicotine-related patent applications in August 2026, including two that approach staged nicotine release from different directions. One uses a high-viscosity membrane that forms inside the pouch after contact with saliva to slow rapid early release, while the other uses gradient particles with a faster-disintegrating outer layer and a slower core to create a fast-to-sustained release profile. Together, the filings explore how nicotine pouches could balance initial delivery with release later in use.
Sep.03
After Apple Business Decline, South Korea’s ITM Semiconductor Expands KT&G Vape Supply Chain as Vape Revenue Rises 24.8%
After Apple Business Decline, South Korea’s ITM Semiconductor Expands KT&G Vape Supply Chain as Vape Revenue Rises 24.8%
South Korean electronics component supplier ITM Semiconductor is reshaping its business portfolio after a decline in Apple-related protection circuit business, expanding its supply of vape devices and cartridges to KT&G. According to News1 on August 18, 2026, ITM’s vape-related revenue rose 24.8% year on year to 75.5 billion won in the first half of 2026. The company began mass production of vape devices at its Cikarang, Indonesia facility in January 2026, strengthening export manufacturing capacity. Meanwhile, Samsung-related protection circuit sales continued to grow, providing support during the transition.
Aug.20
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
NEXTECH launched its NEXE Pro circumferential-heating tobacco stick globally at InterTabac 2026, as the company expands from product innovation into broader heated tobacco solutions. Amid intensifying competition across global HTP markets, NEXTECH is strengthening its R&D, manufacturing and pre-launch support capabilities to serve different types of business customers.
Industry Insight
Sep.15
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Philip Morris Korea launched TEREA Limona Pearl in South Korea on August 31, 2026, expanding the TEREA Fresh Blend capsule tobacco stick lineup from four variants to five. Designed for the IQOS ILUMA series, the new stick combines a capsule with what the company calls a Fresh Filter. Philip Morris Korea describes the product as offering an aromatic, refreshing flavor profile with a cooling sensation, with an additional fresh note released when the capsule is crushed. The recommended retail price is KRW 4,800 per pack, with sales through IQOS stores and convenience stores nationwide. No reliable evidence has been found that the same Limona Pearl SKU was previously officially launched in another major IQOS market.
Sep.01
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26